Mitochondrial response to the BCKDK-deficiency: Some clues to understand the positive dietary response in this form of autism
Por:
De Oyarzabal-Sanz AL, Bravo-Alonso I, Sánchez-Aragó M, Rejas MT, Merinero B, Garcia-Cazorla A, Artuch-Iriberri R, Ugarte M and Rodríguez-Pombo P
Publicada:
1 abr 2016
Resumen:
Mutations on the mitochondrial-expressed Branched Chain of-Keto acid
Dehydrogenase Kinase (BCKDK) gene have been recently associated with a
novel dietary-treatable form of autism. But, being a mitochondrial
metabolism disease, little is known about the impact on mitochondrial
performance. Here, we analyze the mitochondrial response to the
BCKDK-deficiency in patient's primary fibroblasts by measuring
bioenergetics, ultra structural and dynamic parameters. A two-fold
increase in superoxide anion production, together with a reduction in
ATP-linked respiration and intracellular ATP levels (down to 60%)
detected in mutants fibroblasts point to a general bioenergetics
depletion that could affect the mitochondrial dynamics and cell fate.
Ultrastructure analysis of BCKDK-deficient fibroblasts shows an
increased number of elongated mitochondria, apparently associated with
changes in the mediator of inner mitochondria membrane fusion, GTPase
OPA1 forms, and in the outer mitochondria membrane, mitofusin 2/MFN2.
Our data support a possible hyperfusion response of BCKDK-deficient
mitochondria to stress. Cellular fate also seems to be affected as these
fibroblasts show an altered proportion of the cells on G0/G1 and G2/M
phases. Knockdown of BCKDK gene in control fibroblasts recapitulates
most of these features. Same BCKDK-knockdown in a MSUD patient
fibroblasts unmasks the direct involvement of the accelerated BCAAs
catabolism in the mitochondrial dysfunction. All these data give us a
clue to understand the positive dietary response to an overload of
branched-chain amino acids. We hypothesize that a combination of the
current therapeutic option with a protocol that considers the oxidative
damage and energy expenditure, addressing the patients' individuality,
might be useful for the physicians. (C) 2016 Elsevier B.V. All rights
reserved.
Filiaciones:
De Oyarzabal-Sanz AL:
Centro de Diagnóstico de Enfermedades Moleculares (CEDEM), Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), U-746 Centro de Investigación Biomédica en Red de Enfermedades Raras CIBERER-ISCIII, IDIPAZ, Universidad Autónoma de Madrid, Spain
Bravo-Alonso I:
Centro de Diagnóstico de Enfermedades Moleculares (CEDEM), Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), U-746 Centro de Investigación Biomédica en Red de Enfermedades Raras CIBERER-ISCIII, IDIPAZ, Universidad Autónoma de Madrid, Spain
Sánchez-Aragó M:
Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, (CSIC-UAM), U-713 Centro de Investigación Biomédica en Red de Enfermedades Raras CIBERER-ISCIII, Instituto de Investigación Hospital 12 de Octubre, Universidad Autónoma de Madrid, Spain
Rejas MT:
Servicio de Microscopía Electrónica, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Spain
Merinero B:
Centro de Diagnóstico de Enfermedades Moleculares (CEDEM), Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), U-746 Centro de Investigación Biomédica en Red de Enfermedades Raras CIBERER-ISCIII, IDIPAZ, Universidad Autónoma de Madrid, Spain
Garcia-Cazorla A:
Department of Neurology, Hospital Sant Joan de Déu (HSJD), U-703 CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
Artuch-Iriberri R:
Department of Biochemistry, Hospital Sant Joan de Déu (HSJD), U-703 CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain
Ugarte M:
Centro de Diagnóstico de Enfermedades Moleculares (CEDEM), Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), U-746 Centro de Investigación Biomédica en Red de Enfermedades Raras CIBERER-ISCIII, IDIPAZ, Universidad Autónoma de Madrid, Spain
Rodríguez-Pombo P:
Centro de Diagnóstico de Enfermedades Moleculares (CEDEM), Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), U-746 Centro de Investigación Biomédica en Red de Enfermedades Raras CIBERER-ISCIII, IDIPAZ, Universidad Autónoma de Madrid, Spain.
Bronze
|